Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685
With no approved therapy specifically for CLE at present, current treatments are adapted from systemic lupus erythematosus. Consequently, CLE represents an underserved patient population with high unmet need.
To help address this, Werth, et al. undertook a Phase 2, randomised, double-blind, placebo-controlled study, to examine the safety and efficacy of JAK1 inhibition with FIL and SYK inhibition with LANRA in patients with CLE.